Compare MCFT & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCFT | ZURA |
|---|---|---|
| Founded | 1968 | 2022 |
| Country | United States | United States |
| Employees | N/A | 30 |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 379.3M | 435.0M |
| IPO Year | 2015 | N/A |
| Metric | MCFT | ZURA |
|---|---|---|
| Price | $21.92 | $6.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $22.25 | $11.78 |
| AVG Volume (30 Days) | 162.3K | ★ 472.2K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $284,203,000.00 | N/A |
| Revenue This Year | $9.18 | N/A |
| Revenue Next Year | $8.23 | N/A |
| P/E Ratio | $56.82 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.42 | $0.99 |
| 52 Week High | $26.49 | $7.19 |
| Indicator | MCFT | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 43.75 | 60.93 |
| Support Level | $18.77 | $5.62 |
| Resistance Level | $22.88 | $6.76 |
| Average True Range (ATR) | 0.90 | 0.44 |
| MACD | -0.33 | 0.01 |
| Stochastic Oscillator | 18.97 | 68.09 |
MasterCraft Boat Holdings Inc designs, manufactures, and markets performance sport boats and outboard boats. The company is based in the United States and operates in three brand-specific segments. The MasterCraft segment generates the majority of the company's revenue and includes inboard boats for water skiing, wakeboarding, and wake surfing. The Pontoon segment produces pontoon boats at its Owosso, Michigan facility. Pontoon boats are used for general recreational boating. The Aviara segment produces luxury day boats at its Merritt Island, Florida facility. Aviara boats are used for general recreational boating.
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.